

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No. 11)\*

PRO-PHARMACEUTICALS, INC

\_\_\_\_\_  
(Name of Issuer)

Common Stock

\_\_\_\_\_  
(Title of Class of Securities)

74267T109

\_\_\_\_\_  
(CUSIP Number)

James C. Czirr  
425 Janish Drive  
Sandpoint, ID 83864

\_\_\_\_\_  
Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

April 30, 2010

\_\_\_\_\_  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 11 amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 29, 2010 (the "Schedule 13D"), with respect to the common stock, par value \$0.001 per share (the "Common Stock"), of Pro-Pharmaceuticals, Inc. (the "Issuer").

CUSIP No. 74267T109	
1. Names of Reporting Persons.	
James C. Czirr	
2. Check the Appropriate Box if a Member of a Group (See Instructions)	
(a)	
(b) x	
3. SEC Use Only	
4. Source of Funds (See Instructions)	
PF ; AF	
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
o	
6. Citizenship or Place of Organization	
United States	
Number of Shares Beneficially Owned by Each Reporting Person With:	7. Sole Voting Power
	6,170,168 shares of Common Stock <sup>1</sup>
	8. Shared Voting Power
	48,680,831 shares of Common Stock <sup>2</sup>
	9. Sole Dispositive Power
	6,170,168 shares of Common Stock <sup>1</sup>
	10. Shared Dispositive Power
	48,680,831 shares of Common Stock <sup>2</sup>
11. Aggregate Amount Beneficially Owned by Each Reporting Person	
54,850,999	
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
X	
13. Percent of Class Represented by Amount in Row (11)	
54.3%	
14. Type of Reporting Person (See Instructions)	
IN, HC	

## ITEM 1. SECURITY AND ISSUER

There have been no changes to Item 1 since the Schedule 13D/A filed on June 10, 2009.

## ITEM 2. IDENTITY AND BACKGROUND

There have been no changes to Item 2 since the Schedule 13D/A filed on June 10, 2009.

## ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Item 3 is hereby amended by adding the following paragraphs to the end thereof:

On March 31, 2010, a revocable trust of which the Reporting Person is a beneficiary received 6,000 shares of Common Stock in payment of dividends on 100,000 shares of Series A Convertible Preferred Stock owned by the trust.

On April 30, 2010, 10X Fund purchased, and Issuer sold, (a) 155,000 shares of Series B-2 Preferred Stock (which are convertible into 620,000 shares of Common Stock), (b) a Class A-1 warrant exercisable to purchase 310,000 shares of Common Stock at an exercise price of \$0.50 per share, (c) a Class A-2 warrant exercisable to purchase 310,000 shares of Common Stock at an exercise price of \$0.50 per share, and (d) a Class B warrant exercisable to purchase 1,240,000 shares of Common Stock at an exercise price of \$0.50 per share (collectively, the "Ninth Subsequent Closing Securities"). The purchase price paid by 10X Fund to Issuer for the Ninth Subsequent Closing Securities was \$310,000.

On May 10, 2010, 10X Fund purchased, and Issuer sold, (a) 285,000 shares of Series B-2 Preferred Stock (which are convertible into 1,140,000 shares of Common Stock), (b) a Class A-1 warrant exercisable to purchase 570,000 shares of Common Stock at an exercise price of \$0.50 per share, (c) a Class A-2 warrant exercisable to purchase 570,000 shares of Common Stock at an exercise price of

\$0.50 per share, and (d) a Class B warrant exercisable to purchase 2,280,000 shares of Common Stock at an exercise price of \$0.50 per share (collectively, the “Tenth Subsequent Closing Securities”). The purchase price paid by 10X Fund to Issuer for the Tenth Subsequent Closing Securities was \$570,000.

#### **ITEM 4. PURPOSE OF TRANSACTION**

The second paragraph of Item 4 is hereby deleted.

#### **ITEM 5. INTEREST IN SECURITIES OF THE ISSUER**

(a) Aggregate number and percentage of beneficially owned Common Stock: 54,850,999; 54.3%<sup>3</sup>

(b) Aggregate number of beneficially owned shares of Common Stock with:

Sole power to vote or direct the vote: 6,170,168

Shared power to vote or direct the vote: 48,680,831

Sole power to dispose or direct the disposition: 6,170,168  
Shared power to dispose or direct the disposition: 48,680,831

13D: (c) Transactions effected during the last sixty (60) days or since the most recent filing on Schedule

On March 31, 2010, a revocable trust of which the Reporting Person is a beneficiary received 6,000 shares of Common Stock in payment of dividends on 100,000 shares of Series A Convertible Preferred Stock owned by the trust.

On April 30, 2010, 10X Fund purchased, and Issuer sold, (a) 155,000 shares of Series B-2 Preferred Stock (which are convertible into 620,000 shares of Common Stock), (b) a Class A-1 warrant exercisable to purchase 310,000 shares of Common Stock at an exercise price of \$0.50 per share, (c) a Class A-2 warrant exercisable to purchase 310,000 shares of Common Stock at an exercise price of \$0.50 per share, and (d) a Class B warrant exercisable to purchase 1,240,000 shares of Common Stock at an exercise price of \$0.50 per share (collectively, the "Ninth Subsequent Closing Securities"). The purchase price paid by 10X Fund to Issuer for the Ninth Subsequent Closing Securities was \$310,000.

On May 10, 2010, 10X Fund purchased, and Issuer sold, (a) 285,000 shares of Series B-2 Preferred Stock (which are convertible into 1,140,000 shares of Common Stock), (b) a Class A-1 warrant exercisable to purchase 570,000 shares of Common Stock at an exercise price of \$0.50 per share, (c) a Class A-2 warrant exercisable to purchase 570,000 shares of Common Stock at an exercise price of \$0.50 per share, and (d) a Class B warrant exercisable to purchase 2,280,000 shares of Common Stock at an exercise price of \$0.50 per share (collectively, the "Tenth Subsequent Closing Securities"). The purchase price paid by 10X Fund to Issuer for the Tenth Subsequent Closing Securities was \$570,000.

(d) Name of any other person known to have the right to receive or power to direct dividends from, or the proceeds from the sale of the foregoing securities:

Rod Martin, who is also a managing member of 10X Capital, the general partner of 10X Fund.

(e) N/A

## **ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER**

There have been no changes to Item 6 since the Schedule 13D/A filed on March 29, 2010.

## **ITEM 7. MATERIAL TO BE FILED AS EXHIBITS**

There have been no changes to Item 7 since the Schedule 13D/A filed on March 29, 2010.

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 13, 2010

\_\_\_\_\_  
Date

/s/ Robert J. Mottern

\_\_\_\_\_  
Signature

Robert J. Mottern, attorney in fact for James C. Czirr  
Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

## **Footnotes**

<sup>1</sup> Includes 3,597,268 shares held in the Reporting Person's name; 588,000 and 151,700 shares of Common Stock held in two trusts of which the Reporting Person is a beneficiary; 33,200 shares of Common Stock that are held both by the Reporting Person's minor son and by the Reporting Person under the applicable Uniform Gift to Minors Act for the benefit of his minor son; 500,000 shares of Common Stock received by the Reporting Person pursuant to Issuer's 2009 Incentive Compensation Plan that are subject to forfeiture and will not be fully vested until February 13, 2011; 100,000 shares of the Issuer's Series A 12% Convertible Preferred Stock, which are convertible into 100,000 shares of Common Stock, subject to adjustment as set forth in the Issuer's Designation of Preferences, Rights and Limitations of such preferred stock; 100,000 shares of Common Stock issuable upon the exercise of a warrant with an exercise price of \$1.50 per share; 100,000 shares of Common Stock issuable upon the exercise of a warrant with an exercise price of \$2.00 per share; 500,000 options to purchase Common Stock for \$0.30 per share until February 1, 2015 that are fully vested, and 500,000 options to purchase Common Stock for \$0.30 per share until February 1, 2015 that vest in four equal parts quarterly over one year from February 1, 2010.

<sup>2</sup> The Reporting Person is (a) a Managing Member of 10X Capital Management, LLC ("10X Capital"), a Florida limited liability company and the General Partner of 10X Fund, L.P. ("10X Fund"), a Delaware limited partnership. As such, the Reporting Person may be deemed to have indirect beneficial ownership of all or a portion of the securities owned by 10X Fund, L.P. The beneficial ownership of 10X Fund, L.P. ("10X Fund"), a Delaware limited partnership, includes (a) 3,600,000 shares of the Issuer's common stock ("Common Stock") which 10X Fund has the right to acquire upon conversion of 900,000 shares of the Issuer's Series B-1 Convertible Preferred Stock, (b) 8,400,000 shares of Common Stock which the 10X Fund has the right to acquire upon conversion of 2,100,000 shares of the Issuer's Series B-2 Convertible Preferred Stock, (c) 6,000,000 shares of Common Stock which 10X Fund has the right to acquire upon exercise of eleven (11) Class A-1 Warrants of the Issuer, (d) 6,000,000 shares of Common Stock which 10X Fund has the right to acquire upon exercise of eleven (11) Class A-2 Warrants of the Issuer, (e) 24,000,000 shares of Common Stock which 10X Fund has the right to acquire upon exercise of eleven (11) Class B Warrants of the Issuer, and (f) 680,831 shares which 10X Fund owns outright, for a total of 48,680,831 shares which 10X Fund owns or has the right to acquire upon conversion or exercise of existing securities of the Issuer owned by 10X Fund. All of the securities presently owned by 10X Fund are convertible or exercisable immediately into shares of Common Stock. 10X Fund's beneficial ownership does not include shares of Common Stock which the Issuer has the right to issue to 10X Fund in payment of cumulative dividends on shares of Series B-1 or Series B-2 Convertible Preferred Stock of the Issuer.

<sup>3</sup> Based on 51,742,090 shares of Common Stock outstanding on March 1, 2010.